The analysts have been picking over Wyeth's carcass over the past few days as they assess a string of woeful developments that have left the company stripped of three of its leading drug candidates. With its hep C trial suspended [1]Â at the end of last week, the analysts are raising questions about the company's ability to design trials properly. And a pair of FDA rejections hasn't helped the company's reputation one little bit. Add it all up and you see a big pharma company having a terrible time coming up with new winners to replace its fading stockpile of approved drugs. The next big milestone for Wyeth: New mid-stage data from a study for a new Alzheimer's drug being developed with Elan.
- read the report [2] from Forbes
Related Articles:
Wyeth stock down after several setbacks. Report [3]
ViroPharma, Wyeth halt HCV study. Report [1]
Wyeth, Solvay handed FDA rejection. Report [4]
Solvay expands development pact with Wyeth. Report [5]
FDA demands more data on Wyeth's Pristiq. Report [6]
Links:
[1] http://www.fiercebiotech.com/story/viropharma-wyeth-halt-hcv-study/2007-08-10?utm_medium=nl&utm_source=link
[2] http://www.forbes.com/business/2007/08/10/wyeth-fda-trials-biz-cx_mh_0810wyeth.html
[3] http://www.fiercepharma.com/story/wyeth-stock-down-after-several-setbacks/2007-08-13
[4] http://www.fiercebiotech.com/story/wyeth-solvay-handed-fda-rejection/2007-08-10
[5] http://www.fiercebiotech.com/story/solvay-expands-development-pact-with-wyeth/2007-01-11
[6] http://www.fiercebiotech.com/story/fda-demands-more-data-wyeths-pristiq/2007-07-24